arginine/lysine

ApprovedSmall molecule

arginine/lysine is one of 46 small molecule programs targeting Pancreatic Neuroendocrine Tumor. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Neuroendocrine TumorActive, not recruiting

Pancreatic Neuroendocrine TumorApproved

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Pancreatic Neuroendocrine Tumor

#DrugCompanyPhaseTrials

DTIC-Dome

Afinitor

8 3

Glucophage

Sandostatin

Octreotide

Sutent

5 7

FOLFOX

AstraZeneca

Phase 3

1 8

Zepzelca

Jazz Pharmaceuticals

Phase 2

1 9

Ibrance

Pfizer

Phase 2

1 10

Sandostatin

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic Neuroendocrine Tumor1 trial

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Completed·AAdvanced Accelerator Applications·Phase 4·NCT04524442·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for arginine/lysine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — arginine/lysine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for arginine/lysine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advanced Accelerator Applications company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAdvanced Accelerator Applications

arginine/lysine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News